

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

The logo for EuroEyes, featuring the word "EuroEyes" in white sans-serif font on a dark blue rectangular background.

EuroEyes International Eye Clinic Limited

德視佳國際眼科有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1846)

PROFIT ALERT

This announcement is made by EuroEyes International Eye Clinic Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”, each a “**Director**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2022 (the “**Interim Period**”) and other information currently available to the Board, the Group expects to record a profit attributable to owners of the Company in the range of HK\$45 million to HK\$48 million as compared to that of the corresponding period in 2021, a profit attributable to owners of the Company in the amount of approximately HK\$65.1 million, representing a decrease of approximately 29%.

Based on the information available to the Company immediately preceding the publication of this announcement, the decrease was mainly attributable to (i) the continuous outbreak of the COVID-19 epidemic in the first half of the year and the strict control measures carried out in the People’s Republic of China; (ii) the prolonged construction period of the new Copenhagen clinic due to the COVID-19 control policy in Denmark, which resulted in around 60-day of vacancy for surgery operation; (iii) the lifting of the two-year pandemic inter-country travel restrictions across Europe has shifted consumer interests into vacation travel, delaying operation schedules, which is seen as a one-time seasonal effect; and (iv) Euro depreciation against Hong Kong Dollar (“**HKD**” or “**HK\$**”), resulting in a decrease in profit contribution in HKD terms, thereby affecting the Company’s financial position and performance.

The Company is still in the process of finalising the consolidated financial results for the Interim Period. The information contained in this announcement is only a preliminary assessment by the Board based on the information currently available and the unaudited consolidated management accounts of the Group for the Interim Period, which have not been audited or reviewed by the Company’s external auditor or the audit committee of the Board. The finalised and reviewed results of the Group for the Interim Period may be different from what is disclosed in this announcement.

Shareholders and potential investors of the Company are advised to read carefully the announcement of the interim results of the Group for the Interim Period, which is expected to be published by the end of August 2022.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
EuroEyes International Eye Clinic Limited
Dr. Jørn Slot Jørgensen
Chairman and Executive Director

Hong Kong, 11 August 2022

As at the date of this announcement, the Board comprises Dr. Jørn Slot Jørgensen, Dr. Markus Braun, Dr. Ralf-Christian Lerche, Mr. Jannik Jonas Slot Jørgensen and Professor Dan Zoltan Reinstein as executive Directors; Mr. Marcus Huascar Bracklo as non-executive Director; Mr. Hans Helmuth Hennig, Ms. Katherine Rong Xin and Mr. Philip Duncan Wright as independent non-executive Directors.